RET and neoplasm: While RET gene fusions are not commonly associated with HGSOC, the National Comprehensive Cancer Network (NCCN) guidelines recommend testing for RET gene fusions and administering therapy with selpercatinib in patients whose tumours are positive for these fusions [16,72].